Serveur d'exploration sur le patient édenté

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Spectrum of tardive syndromes: clinical recognition and management

Identifieur interne : 001981 ( Istex/Checkpoint ); précédent : 001980; suivant : 001982

Spectrum of tardive syndromes: clinical recognition and management

Auteurs : Roongroj Bhidayasiri [Thaïlande, États-Unis] ; Suthida Boonyawairoj [Thaïlande]

Source :

RBID : ISTEX:CE3205DAA784C0E4DBA0B20F23C882CF153BFE65

Descripteurs français

English descriptors

Abstract

Tardive syndrome (TS) refers to a group of delayed onset disorders characterised by abnormal movements and caused by dopamine receptor blocking agents (DRBAs). Classical tardive dyskinesia is a specific type of oro-buccal-lingual dyskinesia. However, TS may exist in other forms—for example, stereotypy, dystonia, and akathisia—and frequently occur in combination. The onset typically is insidious and after reaching its maximum severity it often stabilises. Frequently reported risk factors are age, dose and duration of neuroleptic exposure, the use of conventional DRBAs, and co-existing mood disorders. This review highlights the broad spectrum of TS, not limited to classical tardive dyskinesia, as well as the clues for its recognition. Despite challenges in the treatment of TS, dictated by the different phenomenology, severity of TS and the need for ongoing neuroleptic treatment, the authors provide evidence based recommendations for patient management, which is not restricted to only withdrawal of the offending neuroleptics or the selection of an alternative medication, such as clozapine. In a minority of cases with significant functional disability, symptomatic or suppressive treatments should be considered. Recently, there has been a resurgence of stereotactic pallidal surgery for the treatment of TS. Although the efficacy of both pallidotomy and pallidal deep brain stimulation in dystonia has been encouraging, the evidence is still limited.

Url:
DOI: 10.1136/pgmj.2010.103234


Affiliations:


Links toward previous steps (curation, corpus...)


Links to Exploration step

ISTEX:CE3205DAA784C0E4DBA0B20F23C882CF153BFE65

Le document en format XML

<record>
<TEI wicri:istexFullTextTei="biblStruct">
<teiHeader>
<fileDesc>
<titleStmt>
<title>Spectrum of tardive syndromes: clinical recognition and management</title>
<author>
<name sortKey="Bhidayasiri, Roongroj" sort="Bhidayasiri, Roongroj" uniqKey="Bhidayasiri R" first="Roongroj" last="Bhidayasiri">Roongroj Bhidayasiri</name>
</author>
<author>
<name sortKey="Boonyawairoj, Suthida" sort="Boonyawairoj, Suthida" uniqKey="Boonyawairoj S" first="Suthida" last="Boonyawairoj">Suthida Boonyawairoj</name>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:CE3205DAA784C0E4DBA0B20F23C882CF153BFE65</idno>
<date when="2010" year="2010">2010</date>
<idno type="doi">10.1136/pgmj.2010.103234</idno>
<idno type="url">https://api.istex.fr/document/CE3205DAA784C0E4DBA0B20F23C882CF153BFE65/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">006647</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">006647</idno>
<idno type="wicri:Area/Istex/Curation">006647</idno>
<idno type="wicri:Area/Istex/Checkpoint">001981</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">001981</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title level="a">Spectrum of tardive syndromes: clinical recognition and management</title>
<author>
<name sortKey="Bhidayasiri, Roongroj" sort="Bhidayasiri, Roongroj" uniqKey="Bhidayasiri R" first="Roongroj" last="Bhidayasiri">Roongroj Bhidayasiri</name>
<affiliation wicri:level="1">
<country xml:lang="fr">Thaïlande</country>
<wicri:regionArea>Chulalongkorn Comprehensive Movement Disorders Center, Department of Medicine, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok</wicri:regionArea>
<wicri:noRegion>Bangkok</wicri:noRegion>
</affiliation>
<affiliation wicri:level="2">
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, California</wicri:regionArea>
<placeName>
<region type="state">Californie</region>
</placeName>
</affiliation>
<affiliation wicri:level="1">
<country wicri:rule="url">États-Unis</country>
</affiliation>
</author>
<author>
<name sortKey="Boonyawairoj, Suthida" sort="Boonyawairoj, Suthida" uniqKey="Boonyawairoj S" first="Suthida" last="Boonyawairoj">Suthida Boonyawairoj</name>
<affiliation wicri:level="1">
<country xml:lang="fr">Thaïlande</country>
<wicri:regionArea>Chulalongkorn Comprehensive Movement Disorders Center, Department of Medicine, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok</wicri:regionArea>
<wicri:noRegion>Bangkok</wicri:noRegion>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series>
<title level="j">Postgraduate Medical Journal</title>
<title level="j" type="abbrev">Postgrad Med J</title>
<idno type="ISSN">0032-5473</idno>
<idno type="eISSN">1469-0756</idno>
<imprint>
<publisher>The Fellowship of Postgraduate Medicine</publisher>
<date type="published" when="2011-02">2011-02</date>
<biblScope unit="volume">87</biblScope>
<biblScope unit="issue">1024</biblScope>
<biblScope unit="page" from="132">132</biblScope>
</imprint>
<idno type="ISSN">0032-5473</idno>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt>
<idno type="ISSN">0032-5473</idno>
</seriesStmt>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="KwdEn" xml:lang="en">
<term>Abnormal movements</term>
<term>Abnormality</term>
<term>Akathisia</term>
<term>Antipsychotic</term>
<term>Atypical</term>
<term>Atypical antipsychotics</term>
<term>Atypical neuroleptics</term>
<term>Botulinum</term>
<term>Botulinum toxin</term>
<term>Brain stimulation</term>
<term>Classical tardive dyskinesia</term>
<term>Clin</term>
<term>Clozapine</term>
<term>Differential diagnosis</term>
<term>Discontinuation</term>
<term>Disord</term>
<term>Dopamine</term>
<term>Drbas</term>
<term>Dyskinesia</term>
<term>Dystonia</term>
<term>Dystonic</term>
<term>Extrapyramidal</term>
<term>Idiopathic</term>
<term>Involuntary movements</term>
<term>Jankovic</term>
<term>Movement disorders</term>
<term>Myoclonus</term>
<term>Neuroleptic</term>
<term>Neuroleptic exposure</term>
<term>Neuroleptic therapy</term>
<term>Neuroleptic treatment</term>
<term>Parkinsonism</term>
<term>Postgrad</term>
<term>Psychiatry</term>
<term>Psychopharmacol</term>
<term>Receptor</term>
<term>Risk factors</term>
<term>Risperidone</term>
<term>Schizophrenia</term>
<term>Stereotypy</term>
<term>Suppressive</term>
<term>Suppressive agents</term>
<term>Syndrome</term>
<term>Tardive</term>
<term>Tardive akathisia</term>
<term>Tardive dyskinesia</term>
<term>Tardive dystonia</term>
<term>Tardive syndromes</term>
<term>Tic</term>
<term>Toxin</term>
<term>Tremor</term>
<term>Typical neuroleptics</term>
</keywords>
<keywords scheme="Teeft" xml:lang="en">
<term>Abnormal movements</term>
<term>Abnormality</term>
<term>Akathisia</term>
<term>Antipsychotic</term>
<term>Atypical</term>
<term>Atypical antipsychotics</term>
<term>Atypical neuroleptics</term>
<term>Botulinum</term>
<term>Botulinum toxin</term>
<term>Brain stimulation</term>
<term>Classical tardive dyskinesia</term>
<term>Clin</term>
<term>Clozapine</term>
<term>Differential diagnosis</term>
<term>Discontinuation</term>
<term>Disord</term>
<term>Dopamine</term>
<term>Drbas</term>
<term>Dyskinesia</term>
<term>Dystonia</term>
<term>Dystonic</term>
<term>Extrapyramidal</term>
<term>Idiopathic</term>
<term>Involuntary movements</term>
<term>Jankovic</term>
<term>Movement disorders</term>
<term>Myoclonus</term>
<term>Neuroleptic</term>
<term>Neuroleptic exposure</term>
<term>Neuroleptic therapy</term>
<term>Neuroleptic treatment</term>
<term>Parkinsonism</term>
<term>Postgrad</term>
<term>Psychiatry</term>
<term>Psychopharmacol</term>
<term>Receptor</term>
<term>Risk factors</term>
<term>Risperidone</term>
<term>Schizophrenia</term>
<term>Stereotypy</term>
<term>Suppressive</term>
<term>Suppressive agents</term>
<term>Syndrome</term>
<term>Tardive</term>
<term>Tardive akathisia</term>
<term>Tardive dyskinesia</term>
<term>Tardive dystonia</term>
<term>Tardive syndromes</term>
<term>Tic</term>
<term>Toxin</term>
<term>Tremor</term>
<term>Typical neuroleptics</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr">
<term>Psychiatrie</term>
</keywords>
</textClass>
<langUsage>
<language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front>
<div type="abstract">Tardive syndrome (TS) refers to a group of delayed onset disorders characterised by abnormal movements and caused by dopamine receptor blocking agents (DRBAs). Classical tardive dyskinesia is a specific type of oro-buccal-lingual dyskinesia. However, TS may exist in other forms—for example, stereotypy, dystonia, and akathisia—and frequently occur in combination. The onset typically is insidious and after reaching its maximum severity it often stabilises. Frequently reported risk factors are age, dose and duration of neuroleptic exposure, the use of conventional DRBAs, and co-existing mood disorders. This review highlights the broad spectrum of TS, not limited to classical tardive dyskinesia, as well as the clues for its recognition. Despite challenges in the treatment of TS, dictated by the different phenomenology, severity of TS and the need for ongoing neuroleptic treatment, the authors provide evidence based recommendations for patient management, which is not restricted to only withdrawal of the offending neuroleptics or the selection of an alternative medication, such as clozapine. In a minority of cases with significant functional disability, symptomatic or suppressive treatments should be considered. Recently, there has been a resurgence of stereotactic pallidal surgery for the treatment of TS. Although the efficacy of both pallidotomy and pallidal deep brain stimulation in dystonia has been encouraging, the evidence is still limited.</div>
</front>
</TEI>
<affiliations>
<list>
<country>
<li>Thaïlande</li>
<li>États-Unis</li>
</country>
<region>
<li>Californie</li>
</region>
</list>
<tree>
<country name="Thaïlande">
<noRegion>
<name sortKey="Bhidayasiri, Roongroj" sort="Bhidayasiri, Roongroj" uniqKey="Bhidayasiri R" first="Roongroj" last="Bhidayasiri">Roongroj Bhidayasiri</name>
</noRegion>
<name sortKey="Boonyawairoj, Suthida" sort="Boonyawairoj, Suthida" uniqKey="Boonyawairoj S" first="Suthida" last="Boonyawairoj">Suthida Boonyawairoj</name>
</country>
<country name="États-Unis">
<region name="Californie">
<name sortKey="Bhidayasiri, Roongroj" sort="Bhidayasiri, Roongroj" uniqKey="Bhidayasiri R" first="Roongroj" last="Bhidayasiri">Roongroj Bhidayasiri</name>
</region>
<name sortKey="Bhidayasiri, Roongroj" sort="Bhidayasiri, Roongroj" uniqKey="Bhidayasiri R" first="Roongroj" last="Bhidayasiri">Roongroj Bhidayasiri</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/EdenteV2/Data/Istex/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001981 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/Istex/Checkpoint/biblio.hfd -nk 001981 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    EdenteV2
   |flux=    Istex
   |étape=   Checkpoint
   |type=    RBID
   |clé=     ISTEX:CE3205DAA784C0E4DBA0B20F23C882CF153BFE65
   |texte=   Spectrum of tardive syndromes: clinical recognition and management
}}

Wicri

This area was generated with Dilib version V0.6.32.
Data generation: Thu Nov 30 15:26:48 2017. Site generation: Tue Mar 8 16:36:20 2022